title: QiShenYiQi Pills, a Compound Chinese Medicine, Ameliorates Doxorubicin-Induced Myocardial Structure Damage and Cardiac Dysfunction in Rats.
abstract: QiShenYiQi Pills (QSYQ) is a compound Chinese medicine used for treatment of cardiovascular diseases. The present study investigated the effects of QSYQ on the Doxorubicin- (DOX-) induced disorders in rat cardiac structure and function and the possible mechanism underlying. A total of 24 male Sprague-Dawley rats were administrated by intraperitoneal injections with DOX at a dose of 2.5 mg/kg, once every day for a total of 6 times. After the 6th injection, the rats were evaluated by echocardiographic analysis, and the animals with injured heart (n = 14) were divided into 2 groups and further treated with (n = 7) or without (n = 7) QSYQ by gavage at a dose of 0.2 g/day, once a day, over the next 2 weeks. Two weeks after QSYQ treatment, the following variables were assessed: myocardial blood flow (MBF) by Laser-Doppler Perfusion Imager, the ratio of heart weight to body weight (HW/BW), myocardial histology, myocardial content of ATP, AMP, free fatty acids (FFAs) and AMP/ATP by ELISA, and expression of PPAR α , PGC-1 α , and ATP 5D by Western blot. Statistical analysis was performed using one-way ANOVA followed by Turkey test for multiple comparisons. DOX challenge significantly increased left ventricular internal diameter and HW/BW and decreased the thickness of the left ventricular posterior wall, the left ventricle ejection fraction, and the left ventricle fractional shortening. DOX also increased AMP, FFA, and AMP/ATP, decreased ATP, and downregulated the protein content of ATP 5D, PPAR α , and PGC-1 α . All these DOX-induced cardiac insults were attenuated significantly by QSYQ treatment. These results show the potential of QSYQ to ameliorate DOX-induced disorders in cardiac structure and function; this effect may be related to the increase in myocardial ATP content via the upregulation of ATP 5D, PPAR α , and PGC-1 α and the oxidation of FFA.
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing 100142, China ; Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China ; Department of Oncology, The First Affiliated Hospital of Guiyang College of TCM, Guiyang, Guizhou 550002, China.
authors.forename: Dong-Xin
authors.initials: DX
authors.lastname: Tang
authors.forename: Hai-Ping
authors.initials: HP
authors.lastname: Zhao
authors.forename: Chun-Shui
authors.initials: CS
authors.lastname: Pan
authors.forename: Yu-Ying
authors.initials: YY
authors.lastname: Liu
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Wei
authors.forename: Xiao-Yuan
authors.initials: XY
authors.lastname: Yang
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Chen
authors.forename: Jing-Yu
authors.initials: JY
authors.lastname: Fan
authors.forename: Chuan-She
authors.initials: CS
authors.lastname: Wang
authors.forename: Jing-Yan
authors.initials: JY
authors.lastname: Han
authors.forename: Ping-Ping
authors.initials: PP
authors.lastname: Li